Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 4 studies | 29% ± 12% | |
epithelial cell | 4 studies | 32% ± 11% | |
non-classical monocyte | 3 studies | 33% ± 11% | |
intestinal crypt stem cell | 3 studies | 18% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 99% | 1152.20 | 961 / 966 | 100% | 45.44 | 527 / 527 |
lung | 99% | 999.22 | 575 / 578 | 99% | 27.55 | 1149 / 1155 |
pancreas | 99% | 771.36 | 326 / 328 | 99% | 24.52 | 177 / 178 |
bladder | 100% | 513.38 | 21 / 21 | 99% | 33.84 | 498 / 504 |
prostate | 98% | 826.88 | 241 / 245 | 100% | 34.57 | 501 / 502 |
stomach | 97% | 703.39 | 350 / 359 | 100% | 42.41 | 286 / 286 |
liver | 100% | 926.62 | 226 / 226 | 97% | 23.84 | 395 / 406 |
thymus | 99% | 573.08 | 646 / 653 | 98% | 16.94 | 595 / 605 |
esophagus | 98% | 755.10 | 1411 / 1445 | 99% | 32.23 | 182 / 183 |
breast | 94% | 524.78 | 431 / 459 | 100% | 32.52 | 1113 / 1118 |
brain | 95% | 456.90 | 2500 / 2642 | 99% | 17.07 | 695 / 705 |
skin | 99% | 1439.42 | 1786 / 1809 | 94% | 14.07 | 444 / 472 |
uterus | 84% | 332.09 | 143 / 170 | 99% | 38.67 | 456 / 459 |
kidney | 93% | 487.57 | 83 / 89 | 78% | 9.40 | 706 / 901 |
ovary | 67% | 210.24 | 120 / 180 | 100% | 42.99 | 430 / 430 |
adrenal gland | 87% | 330.38 | 225 / 258 | 55% | 5.73 | 126 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 23.53 | 29 / 29 |
spleen | 100% | 2880.18 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.42 | 1 / 1 |
peripheral blood | 98% | 10940.51 | 915 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 40.49 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 98% | 19.08 | 78 / 80 |
adipose | 93% | 447.83 | 1122 / 1204 | 0% | 0 | 0 / 0 |
muscle | 83% | 405.31 | 665 / 803 | 0% | 0 | 0 / 0 |
heart | 74% | 263.16 | 633 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 42% | 144.66 | 560 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046825 | Biological process | regulation of protein export from nucleus |
GO_0060070 | Biological process | canonical Wnt signaling pathway |
GO_0005575 | Cellular component | cellular_component |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003674 | Molecular function | molecular_function |
Gene name | FRAT2 |
Protein name | GSK-3-binding protein FRAT2 (Frequently rearranged in advanced T-cell lymphomas 2) (FRAT-2) |
Synonyms | |
Description | FUNCTION: Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3. |
Accessions | ENST00000371019.4 O75474 |